Deborah Citrin retweeted
Seminars in Radiation Oncology is pleased to share "Software Tools and Simulation Exercises for Radiation Oncology Cyber-Attack Resiliency" by Dr. Yevgeniy Vinogradskiy @JeffersonUniv & Dr. James Lamb @UofCalifornia
sciencedirect.com/science/ar…
Deborah Citrin retweeted
📢Check out the June 1 #RedJournal @IJROBP issue that comes with an appropriately summer-themed cover image & a whopping 5⃣ stellar #radbio articles💪
Ringing in (quote by @sueyom ) a "biology-dense" summer😀
➡️redjournal.org/current
Stay tuned for a couple of amazing bio podcasts coming your way as well❤️❤️
Deborah Citrin retweeted
Today, we’re launching an initiative we’re calling #YourNCI that highlights how valuable the public investment in cancer research is – and how it pays off in cancer prevention, screening, diagnosis, survivorship and better, more effective treatments.
Deborah Citrin retweeted
We invite researchers, clinicians, and the broader community to share their perspectives. Your insights can help shape the future of cancer research and discovery. Share your thoughts below and be part of the conversation.
At #AACR26? Stop by booth #736 to share your perspective in person.
I am so honored to have had the opportunity to collaborate with @BobTimmermanMD to update the NEJM readership on the recent developments in our field that aim to increase efficacy and prevent/mitigate side effects.
𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰 𝗨𝗻𝗱𝗲𝗿𝗽𝗶𝗻𝗻𝗶𝗻𝗴𝘀 𝗼𝗳 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁𝘀 𝗼𝗳 𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻
Radiobiologic models developed with the use of characteristics such as mitotic capacity, tissue hierarchy, and differentiation state can predict responses in normal tissue at the levels of the cell, tissue, and organ. For example, the interaction of the dose and volume of radiation with the risk of effects in normal tissue is tissue- or organ-specific and dependent on the organization of the smallest functional subunits (e.g., nephrons, neurons, or alveoli) within the tissue. For some organs in which the functional subunits are organized in parallel (e.g., nephrons in the kidney), approximately a third of the total volume of the organ must be spared from receiving a relatively low threshold dose to maintain functional organ viability. The remaining two thirds of the organ constitutes a functional reserve. In contrast, when functional subunits are arranged in series (e.g., spinal cord neurons), even a focal injury threatens organ function (e.g., spinal cord myelopathy). Tissues with parallel organization generally have a higher tolerance for radiation than tissues with serial organization. Ablative treatments such as stereotactic ablative radiotherapy are more likely to have an acceptable safety profile when applied in and around tissues with parallel organization or in tissues capable of compensatory hyperplasia after injury than in serially functioning tissues (seen in figure).
Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…
𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰 𝗨𝗻𝗱𝗲𝗿𝗽𝗶𝗻𝗻𝗶𝗻𝗴𝘀 𝗼𝗳 𝗦𝗶𝗱𝗲 𝗘𝗳𝗳𝗲𝗰𝘁𝘀 𝗼𝗳 𝗥𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻
Radiobiologic models developed with the use of characteristics such as mitotic capacity, tissue hierarchy, and differentiation state can predict responses in normal tissue at the levels of the cell, tissue, and organ. For example, the interaction of the dose and volume of radiation with the risk of effects in normal tissue is tissue- or organ-specific and dependent on the organization of the smallest functional subunits (e.g., nephrons, neurons, or alveoli) within the tissue. For some organs in which the functional subunits are organized in parallel (e.g., nephrons in the kidney), approximately a third of the total volume of the organ must be spared from receiving a relatively low threshold dose to maintain functional organ viability. The remaining two thirds of the organ constitutes a functional reserve. In contrast, when functional subunits are arranged in series (e.g., spinal cord neurons), even a focal injury threatens organ function (e.g., spinal cord myelopathy). Tissues with parallel organization generally have a higher tolerance for radiation than tissues with serial organization. Ablative treatments such as stereotactic ablative radiotherapy are more likely to have an acceptable safety profile when applied in and around tissues with parallel organization or in tissues capable of compensatory hyperplasia after injury than in serially functioning tissues (seen in figure).
Learn more in the Review Article “Effects of Radiotherapy in Normal Tissue” by @DeborahCitrin, MD, and Robert D. Timmerman, MD (@BobTimmermanMD), from the National Cancer Institute and @UTSWMedCenter: nejm.org/doi/full/10.1056/NE…
Deborah Citrin retweeted
📢The February issue of the #RedJournal is out and it has soooo much great #radbio in it🔥🔥🔥
Where to begin❓
Highly timely review: Radiation-Induced Lymphopenia: From Mathematical Modeling Toward Mechanistic Learning ‼️
⚠️OPEN ACCESS redjournal.org/article/S0360…
With accompanying commentary by @CGrassberger & Team🙏🙏🙏
⚠️redjournal.org/article/S0360…
Deborah Citrin retweeted
🔊Worth listening to:
#RedJournal #RadBio #immunooncology Podcast December 1, 2025: Irradiating Elective Nodal Volumes – When and How?
➡️redjournal.org/issue/S0360-3…
@sueyom with Claire Vanpouille-Box, Tsubasa Watanabe, Genki Sato, @jdschoenfeld1 🙏🙏🙏
Deborah Citrin retweeted
📢Another great #radbio review in the @IJROBP #RedJournal
Informative review on the enigmatic MYC transcription factor & potential role of MYC inhibitors for #radiotherapy‼️
@sueyom @DeborahCitrin @CellDeathLab
PDF 👉redjournal.org/action/showPd…
redjournal.org/article/S0360…
Deborah Citrin retweeted
SEEKING PARTICIPANTS: An NCI #ClinicalTrial is researching immunotherapy for people with #ThroatCancer. The trial will take place at the @NIHClinicalCntr in Maryland, and there is no cost for medical care or participation. go.nih.gov/CZrIi5z #HeadAndNeckCancer

ALT Clinical Trial Now Enrolling: Clinical trial researching immunotherapy for throat cancer. Trial adding immunotherapy to chemotherapy drugs to improve survival without the need for radiation. At the NIH Clinical Center in Bethesda, MD. No cost for medical care received at the Clinical Center; travel allowances may apply. ClinicalTrials.gov ID: NCT06223568. Have a patient to refer? Contact the NCI Cancer Information Service at 1-888-624-1937 or [email protected]
Deborah Citrin retweeted
With heavy hearts, we remember & honor Dr. Felix Feng. May his memory be a blessing. 💝💝💝
donate.cancer.org/g/tjjfqwdn…
Deborah Citrin retweeted
A randomized trial showed noninferiority of stereotactic body radiotherapy to conventionally or moderately hypofractionated radiotherapy in preventing biochemical recurrence in selected men with localized prostate cancer. Full PACE-B trial results: nej.md/3Y7coBm
Deborah Citrin retweeted
1/
#ASTRO24
📢@drjefstathiou @MGHCancerCenter taking it away:
Protons vs IMRT in #ProstateCancer 🔥🔥‼️
@sueyom @IJROBP
Deborah Citrin retweeted
Outstanding presentation by @drjefstathiou #ASTRO24 showing no improvement in any outcome with proton therapy for localised prostate cancer compared to photon therapy. Congratulations to all authors! 👏
Agree, the rates of G3+ are higher than I would expect. It will be interesting to see the publication when available.
Replying to @IBCradiation
Hmmm those are quite high pneumonitis numbers. Curious that steroids during RT would be effective like that? @DeborahCitrin


























